Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | FABP6 | P51161 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12474749 | 0.81 | ALDH1A1 (0.34) | ARALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL2361983 | 0.79 | ALDH1A1 (0.37) | ARCDK4CDK6PIK3CDBTK | |
| SCHEMBL29620781 | 0.76 | ALDH1A1 (0.35) | ARNR3C1PGRCDK4CDK6 | |
| SCHEMBL21372201 | 0.76 | ALDH1A1 (0.35) | ARCDK4CDK6PIK3CDBTK | |
| SCHEMBL13035938 | 0.76 | ALDH1A1 (0.35) | ARNR3C1PGRCDK4CDK6 | |
| SCHEMBL12116975 | 0.76 | ALDH1A1 (0.50) | ARCDK4CDK6PIK3CDBTK | |
| SCHEMBL8191693 | 0.73 | PGR (0.43) | ARNR3C1PGRALDH1A1 | |
| SCHEMBL3328643 | 0.72 | AR (0.35) | ARCDK4CDK6PIK3CDBTK | |
| SCHEMBL3329757 | 0.72 | DHFR (0.34) | ARCDK4CDK6PIK3CDBTK | |
| SCHEMBL16655910 | 0.72 | PIK3CD (0.33) | ARCDK4CDK6PIK3CDBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Etern Therapeutics Hongkong Limited (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4484420-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023155927-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海奕拓医药科技有限责任公司 | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | YAP1, YES1, TEAD2 | AR 3214/4885NR3C1 4299/4885PGR 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.